Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cytos Biotechnology AG to Discontinue NIC002 Project Due to Negative Trial Results


Wednesday, 23 Jan 2013 01:15am EST 

Cytos Biotechnology AG announced that Novartis will discontinue the NIC002 project for the treatment of nicotine addiction. Already communicated in October 2009 were results from a Phase 2 study with NIC002 vaccine conducted by Novartis that showed formation of nicotine-specific antibodies in patients but did not meet its primary endpoint of increased smoking cessation. As a result of the discontinuation, Novartis will terminate the licence granted in 2007 and will return to Cytos the licensed rights pursuant to the provisions of the licence agreement. A second collaboration with Novartis on CAD106 in development for the treatment of patients with Alzheimer's Disease is not affected by this decision. 

Related Company News

Company Quote

0.24
-0.01 -4.00%
10 Jul 2014